Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
Researchers have developed an organ-on-a-chip model that will allow for preclinical testing in an environment analogous to the human gastrointestinal tract.
Crown Bioscience has announced the acquisition of PreClinOmics, an in vivo preclinical company specializing in early research in cardiovascular and metabolic diseases (CVMD).
The WHO has accused biopharma firms of failing to invest in R&D to tackle Ebola due to the disease’s prevalence in poor African nations, as the death toll surpasses 4,000.
France has placed itself firmly at the forefront of research into
personalised medical solutions for cancer, infectious diseases and
rare genetic diseases by investing nearly half a billion euros into
the ADNA project.
Scientists have come up with an innovative tool that may accelerate
the drug development process, which has slowed down considerably
despite the investment in new technologies and analytical
techniques.
